Bio-Rad price target lowered to $345 from $360 at Wells Fargo

Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $345 from $360 and keeps an Equal Weight rating on the shares. The firm says 2025 will be about self-help and new management executing on margins and free cash flow. Valuation has moved up, but still implies status quo, it adds. Wells sees Bio-Rad as more a second half of the year story when visibility on 2026/2027 EPS/free cash flow power improves.